An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Eisai Inc
- 27 Sep 2017 Planned End Date changed from 31 Mar 2019 to 1 Oct 2018.
- 27 Sep 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Feb 2018.
- 28 Oct 2016 Status changed from not yet recruiting to recruiting, as per Eisai media release.